Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06422208 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease

StatusEnrolling by Invitation
PhasePhase 1
Started2024-08-07
View on ClinicalTrials.gov ↗
This research study is evaluating an investigational cell product called autologous induced pluripotent stem cell (iPSC)-derived dopamine neurons. This research study is a single-center Phase 1/2a clinical trial, which will test the safety of injecting the investigational cell product into the brain of subjects with Parkinson's disease.

Amendment history 3 changes detected by DataLookout

2026-09-16
Enrollment increased: 6 → 12 participants
2026-09-16
Primary completion pushed: 2026-12 → 2028-12
2026-09-16
Completion pushed: 2027-12 → 2028-12
Trial Details
NCT Number NCT06422208
Lead Sponsor Penelope J. Hallett, Ph.D.
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS), Oryon Cell Therapies
Conditions Parkinson Disease
Enrollment 12 participants
Start Date 2024-08-07
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-15